Pulmonx Corp
LUNG
Get informed when a big investor buys or sells
+ FollowMarket Cap$54.06M
Close$
Share Statistics
| Market cap | $54.06 Million |
|---|---|
| Enterprise Value | $49.15 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.33 |
| Beta | 0.28 |
| Outstanding Shares | 41,897,669 |
Return
| Return on Equity | -116.28% |
|---|---|
| Return on Assets | -44.35% |
| Return on Invested Capital | -52.66% |
Valuation & Multiples
| P/E Ratio | -1.01 |
|---|---|
| PEG | 18.34 |
| Price to Sales | 0.64 |
| Price to Book Ratio | 1.28 |
| Enterprise Value to Revenue | 0.56 |
| Enterprise Value to EBIT | -0.92 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.15 |
| Debt to Equity | 1.24 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 5, 2026
EPS Estimate
$-0.33
Average shareholder expectationRevenue Estimate
$20.43 M
Average shareholder expectationNext Earnings Call
Expected Date
July 29, 2026
EPS Estimate
$-0.28
Average shareholder expectationRevenue Estimate
$22.39 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 231.96% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | 107,600▼ 16.72% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 76.68%▼ 2.45% |
|---|---|
| Total Invested | $40.96M▼ 42.78% |
| Investors Holding | 115▼ 1.00% |
ESG Score
No data
About Pulmonx Corp
220 employeesPulmonx Corporation is a commercial-stage medical technology company. The Company is focused on providing planning tools and treatments for obstructive lung disease. Its solutions include Zephyr Valve, Chartis Pulmonary Assessment System...